Which colonoscopy prep works best for diabetics? new trial aims to find out

NCT ID NCT07351019

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Aug 07, 2026 · Updated 3 times

Summary

This study compares two bowel cleansing solutions, Golytely and SUPREP, for colon cancer screening in people with diabetes. Researchers want to see which one cleans the colon better and is easier to tolerate. About 80 participants will be randomly assigned to one of the two preps and then rate their experience. The goal is to improve colonoscopy quality for diabetic patients.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Golytely and SUPREP (bowel cleansing solutions)
What this could lead to
If successful, this study could help doctors choose the best bowel prep for diabetic patients, improving colonoscopy quality and comfort.
What could go wrong
This is a small, early-phase trial with only 80 participants, so results may not apply to all diabetics. The study compares existing drugs, not a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

64 people

The number who actually took part.

Started

Jan 2026

Finished

Jul 2026

Lead sponsor

A government agency

The lead sponsor is a US federal agency other than the NIH.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Participants having provided informed consent with signature on informed consent form: the informed consent process should be complete with full discussion of all requirements and possible risks. 2. Diabetic volunteer (defined per current ACP guidelines, and any type of DM) 3. Aged 18+ years, inclusive 4. Average screening risk, polyp surveillance, and family history of cancer Exclusion Criteria: 1. Unable to provide informed consent to participate in the study Such as a mental condition rendering the participant unable to understand the nature, scope, and possible consequences of the study 2. Clinically relevant cardiovascular, hepatic, neurological, endocrine, or other major systemic disease making implementation of the protocol or interpretation of the study results difficult or that would put the participant at risk by participating in the study 3. Persistent significant or severe infection, either acute or chronic 4. Prior use of any investigational drug in the preceding 6 months 5. Liver function impairment or persisting elevations (confirmed by retest) of alanine aminotransferase (ALT), aspartate aminotransferase (AST), or direct bilirubin greater than 2x the upper limit of normal range (ULN). 6. Pregnant or breast-feeding women or those who plan to become pregnant during the study 7. Participants with significantly impaired bone marrow function or significant anemia, leukopenia, or thrombocytopenia (confirmed by retest): 1. Hematocrit \< 35% and/or 2. Absolute white blood cell count \< 3000 cells/mm3 ( L) and/or 3. Platelet count \< 150 000 cells/mm3 ( L) and/or- Absolute neutrophil = 1500 cells/mm3 ( L) 8. History of colorectal cancer 9. Inflammatory Bowel Disease 10. Past surgical history of colon resection 11. Prior history of colorectal surgery 12. Family history of hereditary polyposis and cancer disorders to include but not limited to FAP (Familial Adenomatous Polyposis), Gardner Syndrome, Turcot Syndrome, Lynch Syndrome, Cowden Syndrome, and Peutz-Jeghers Syndrome 13. Symptomatic patients (bleeding, diarrhea, constipation, abdominal pain)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Colon cancer screening are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Dwight D. Eisenhower Army Medical Center

    Fort Gordon, Georgia, 30905, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.